All In Biotech

Drug Trial Radar · NCT04612972

Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru

Ensayo Clínico de Fase III, Aleatorio, Doble Ciego y Controlado Con Placebo Paralelo, Para Evaluar la Seguridad y la Eficacia Protectora de la Vacuna Inactivada Contra el SARS-CoV-2 en la Población Sana de 18 años o más, en Perú

Last checked: Nov 20, 2026Latest source record: May 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 12,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,000

Actual

Start

Sep 9, 2020

Primary completion

Feb 19, 2021

Study completion Apr 3, 2023

Sponsor

Lead sponsor
Universidad Peruana Cayetano HerediaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National University of San Marcos, Peru
First posted
Nov 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.

Conditions

  • COVID-19

Interventions

  • Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/PlaceboBiological

    This clinical trial is conducted in randomized, blind, placebo controlled design Total sample size is 12 000, which are randomly allocated into investigational vaccine 1, investigational vaccine 2 and placebo control group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of confirmed Covid-19 cases in the two vaccine groups and the placebo group.Time frame: One year beginning on day 14 after the second dose of immunization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Av. Honorio Delgado 430, Urb. Ingeniería

    San Martín de Porres, Lima region, Peru

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.